**Supplementary Table 3.** **Reliability assessment of the results of NAFL group vs. controls by the GRADE approach**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **NAFL compared to control for resistin level** | | | | | | |
| **Patient or population:** Patients with  **Settings of**  **Intervention:** NAFL **Comparison:** Control | | | | | | |
| **Outcomes** | **Illustrative comparative risks\* (95% CI)** | | **Relative effect (95% CI)** | **No of Participants (studies)** | **Quality of the evidence (GRADE)** | **Comments** |
| **Assumed risk** | **Corresponding risk** |
|  | **Control** | **NAFL** |  |  |  |  |
| **resistin level** |  | The mean resistin level in the intervention groups was **0.03 standard deviations higher** (0.23 lower to 0.29 higher) |  | 261 (6) | ⊕⊕⊕⊝ **moderate**1 | SMD 0.03 (-0.23 to 0.29) |
| \*The basis for the **assumed risk** (e.g., the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). | | | | | | |
| GRADE Working Group grades of evidence **High quality:** Further research is very unlikely to change our confidence in the estimate of effect.  **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. **Very low quality:** We are very uncertain about the estimate. | | | | | | |
| 1The level of resistin is closely related to the degree of NAFLD. | | | | | | |